Abstract 1935
Background
Primary treatments for stage IV breast cancer are chemotherapy and endocrine therapy. We sought to determine whether multidisciplinary therapy provides a survival advantage for women with metastatic breast cancer.
Methods
We conducted a population-based cohort study by using the 2010-2014 Surveillance, Epidemiology, and End Results (SEER) program data. By use of the log-rank test and multivariate cox regression models, overall survival in patients was compared between women who underwent different combination modes of surgery, radiotherapy and chemotherapy, controlling for potential confounding demographic, tumor- and treatment-related variables, and propensity scores.
Results
Of 17191 SEER patients with de novo stage IV breast cancer, 29.4% underwent surgery, 32.3% received radiotherapy and 49.6% received chemotherapy. The median follow-up was 28.0 months for all patients. The median survival time of combined surgery, chemotherapy and radiotherapy(SCRT), combined surgery and radiotherapy(SRT),combined surgery and chemotherapy(SC), combined chemotherapy and radiotherapy (CRT), surgery alone, chemotherapy alone, radiotherapy alone and no therapy were 51.0m (95%CI, NR), 46m (95%CI, 39.7-52.3), 37.0m (95%CI, 33.4-40.6), 22.0m (95%CI, 20.0-24.0), 29.0m (95%CI, 25.3-32.7), 26.0m (95%CI, 24.5-27.5), 22.0m (95%CI, 19.9-24.1) and 13.0m (95%CI, 11.8-14.2), respectively (p<0.001). After controlling for potential confounding variables and propensity scores, patients who underwent surgery, radiotherapy and chemotherapy were less likely to die compared with patients who did not undergo surgery, radiotherapy and chemotherapy,respectively (HR = 0.32, 95% CI, 0.30-0.34, p<0.001, HR = 0.40, 95%CI, 0.38-0.43, p<0.001 and HR = 0.51, 95%CI, 0.48-0.54, p<0.001). There was no statistically significant difference among patients with different breast cancer subtype.
Conclusions
Analysis of 2010-2014 SEER data indicated that multidisciplinary approach is especially important in the management of newly diagnosed metastatic breast cancer to consider all potential treatment options for optimal outcomes.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jian Zhang.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3536 - Palbociclib plus an aromatase inhibitor as first-line therapy for metastatic breast cancer in US clinical practices: Real-world progression-free survival analysis
Presenter: Mylin Torres
Session: Poster Display session 2
Resources:
Abstract
4022 - Ribociclib (RIB) plus letrozole (LET) in male patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from the CompLEEment-1 trial
Presenter: Mario Campone
Session: Poster Display session 2
Resources:
Abstract
3599 - Comparative effectiveness of palbociclib plus letrozole vs letrozole for metastatic breast cancer in US real-world clinical practices
Presenter: Rachel Layman
Session: Poster Display session 2
Resources:
Abstract
901 - Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumors
Presenter: Yung-Jue Bang
Session: Poster Display session 2
Resources:
Abstract
2777 - A Phase 2 study of abemaciclib in patients (pts) with brain metastases (BM) secondary to non-small cell lung cancer (NSCLC) or melanoma (MEL).
Presenter: Solmaz Sahebjam
Session: Poster Display session 2
Resources:
Abstract
3980 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with visceral metastases (VM) or bone-only metastases (BOM) in hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Subgroup analysis from the CompLEEment-1 trial
Presenter: Michelino De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
4024 - Ribociclib (RIB) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) and central nervous system (CNS) metastases: Subgroup analysis from the phase 3b CompLEEment-1 trial
Presenter: Paul Cottu
Session: Poster Display session 2
Resources:
Abstract
2151 - Clinical outcome and toxicity data in patients with advanced breast cancer treated with cyclin-dependent kinase 4/6 (CDK4/6) inhibitors combined with endocrine therapy in a real-world clinical setting.
Presenter: Elena Fountzilas
Session: Poster Display session 2
Resources:
Abstract
3994 - Safety and efficacy of Ribociclib (RIBO) + letrozole (LET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced breast cancer (ABC): Interim results from the Italian cohort of the CompLEEment-1 (C-1) study.
Presenter: Michele De Laurentiis
Session: Poster Display session 2
Resources:
Abstract
1370 - Interim Results From CompLEEment-1 (A Phase 3b Study of Ribociclib and Letrozole as First-Line Therapy for Advanced Breast Cancer in an Expanded Population): Spanish cohort results
Presenter: Javier Salvador
Session: Poster Display session 2
Resources:
Abstract